Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations-Reference-Cited by-同舟云学术

Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations

Published:2014-04 Issue:2 Volume:151 Page:127-135
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Miyazaki Yusei,Niino Masaaki,Fukazawa Toshiyuki,Takahashi Eri,Nonaka Takayuki,Amino Itaru,Tashiro Jun,Minami Naoya,Fujiki Naoto,Doi Shizuki,Kikuchi Seiji

Funder

Ministry of Health, Labor and Welfare of Japan

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference36 articles.

1. The Immune modulator FTY720 targets sphingosine 1-phosphate receptors;Brinkmann;J. Biol. Chem.,2002

2. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors;Gräler;FASEB J.,2004

3. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists;Mandala;Science,2002

4. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis;Mehling;Neurology,2011

5. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy;Ingwersen;Clin. Immunol.,2012

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination;Frontiers in Immunology;2024-07-15

2. Modification of T- and B-cell-associated immuno-pathologic mechanisms in multiple sclerosis by disease modifying therapies: Achievements and opportunities;Handbook of Clinical Neurology;2024

3. The effect of fingolimod drug on blood profile in multiple sclerosis patients;4TH INTERNATIONAL SCIENTIFIC CONFERENCE OF ALKAFEEL UNIVERSITY (ISCKU 2022);2023

4. B-Cell Targeted Therapies in Patients with Multiple Sclerosis and Incidence of Headache: A Systematic Review and Meta-Analysis;Journal of Personalized Medicine;2022-09-08

5. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod;Journal of Neurology;2022-03-02